Immage Biotherapeutics Corp(IMMG)
USD --+0.00%
Reward40Moderate
Risk63Medium-High
📊75%Data
IMMG
+0.0 · +0.00%
USD · OTCCE
Immage Biotherapeutics Corp | Healthcare
Capital Destroyer
Market Cap:15174
ℹ️
Reward Rating
40
Moderate
Bottom 10% (model universe)
75% data coverage
ℹ️
Risk Rating
63
Medium-High
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on IMMG to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Immage Biotherapeutics Corp?

does not have significant business operations.

IMMG · Verdict

Moderate reward · elevated risk

IMMG's standout is balance sheet; cash flow and volatility weigh on the picture.

Based on 88% data coverage

IMMG · Verdict

What’s working & what to watch

Strengths 1

  • Balance sheet92/100

    Current ratio 3.67

Watchouts 4

  • Cash flow5/100

    Weak vs peers

  • Volatility5/100

    Weak vs peers

  • Profitability10/100

    -1134% return on equity

  • Growth41/100

    Earnings +162.2% CAGR

Model-based scoring. For information only — not financial advice.

What is Immage Biotherapeutics Corp?

does not have significant business operations. Previously, it was engaged in developing novel immunotherapy biologics to treat various cancers in the United States. The company is listed on the OTCCE in USA, operating in the Healthcare sector, with a market capitalisation of 15.17K.

Financial Highlights

Investment Breakdown

📈 Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
💰 Profitability
Thin or inconsistent margins weigh on earnings quality.
⚠️ Risk
Moderate volatility with meaningful macro and earnings sensitivity.
💸 Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (40)

The scoring profile indicates limited reward potential at this time, with valuation and momentum offering the most support. Risk indicators are elevated — volatility and macro sensitivity warrant consideration.

For informational purposes only. Not financial advice.

Company Information
SectorHealthcare
Market Cap15.17K
P/E RatioN/A
Dividend YieldN/A
52 Week High0.0001
52 Week Low0.0001
Last AnnualAugust
IPO DateN/A
IncorporatedUSA
Shares Outstanding152M
No. of Employees3
IndustryBiotechnology
ExchangeOTCCE
Beta54.9
CurrencyUSD